EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 / No 11 (Novembre 2016) Med Sci (Paris), 32 11 (2016) 991-997 References
Free Access
Issue
Med Sci (Paris)
Volume 32, Number 11, Novembre 2016
Le microbiote : cet inconnu qui réside en nous
Page(s) 991 - 997
Section Le microbiote : cet inconnu qui réside en nous
DOI https://doi.org/10.1051/medsci/20163211015
Published online 23 December 2016
  1. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012 ; 107 : 1755–1756. [CrossRef] [Google Scholar]
  2. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958 ; 44 : 854–859. [PubMed] [Google Scholar]
  3. Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation : current clinical efficacy and future prospects. Clin Exp Gastroenterol 2015 ; 8 : 285–291. [CrossRef] [PubMed] [Google Scholar]
  4. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011 ; 53 : 994–1002. [CrossRef] [PubMed] [Google Scholar]
  5. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013 ; 368 : 407–415. [CrossRef] [PubMed] [Google Scholar]
  6. Singh R, Nieuwdorp M, ten Berge IJ, et al. The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection. Clin Microbiol Infect 2014 ; 20 : 1119–1125. [CrossRef] [PubMed] [Google Scholar]
  7. Lagier JC. Faecal microbiota transplantation : from practice to legislation before considering industrialization. Clin Microbiol Infect 2014 ; 20 : 1112–1118. [CrossRef] [PubMed] [Google Scholar]
  8. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases : update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014 ; 20 (suppl 2) : 1–26. [CrossRef] [Google Scholar]
  9. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014 ; 109 : 1065–1071. [CrossRef] [Google Scholar]
  10. Lagier JC, Delord M, Million M, et al. Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route : a preliminary report. Eur J Clin Microbiol Infect Dis 2015 ; 34 : 1597–1601. [CrossRef] [PubMed] [Google Scholar]
  11. Lagier JC, Dubourg G, Cassir N, et al. Clostridium difficile 027 emerging outbreak in Marseille, France. Infect Control Hosp Epidemiol 2013 ; 34 : 1339–1341. [CrossRef] [PubMed] [Google Scholar]
  12. Million M, Hocquart M, Seghboyan JM, et al. Faecal microbiota transplantation as salvage therapy for fulminant Clostridium difficile infections. Int J Antimicrob Agents 2015 ; 46 : 227–228. [CrossRef] [PubMed] [Google Scholar]
  13. Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection : A multicenter experience. J Clin Gastroenterol 2016 ; 50 : 398–402. [PubMed] [Google Scholar]
  14. Lagier JC, Raoult D. Deadly infectious diseases such as Ebola : the parachute paradigm. Clin Microbiol Infect 2015 ; 21 : 389–390. [CrossRef] [PubMed] [Google Scholar]
  15. Haut conseil de la Santé Publique. Prévention de la transmission croisée des bactéries hautement résistantes aux antibiotiques émergentes (BHRe) Paris : HCSP, 2013 : 1–79. [Google Scholar]
  16. Singh R, van NE, Nieuwdorp M, et al. Donor feces infusion for eradication of extended spectrum beta-Lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect 2014 ; 20 : 977–978. [CrossRef] [Google Scholar]
  17. Lagier JC, Million M, Fournier PE, et al. Faecal microbiota transplantation for stool decolonization of OXA-48 carbapenemase-producing Klebsiella pneumoniae. J Hosp Infect 2015 ; 90 : 173–174. [CrossRef] [PubMed] [Google Scholar]
  18. Stripling J, Kumar R, Baddley JW, et al. Loss of vancomycin-resistant enterococcus fecal dominance in an organ transplant patient with clostridium difficile colitis after fecal microbiota transplant. Open Forum Infect Dis 2015 ; 2 : ofv078. [CrossRef] [PubMed] [Google Scholar]
  19. Wei Y, Gong J, Zhu W, et al. Fecal microbiota transplantation restores dysbiosis in patients with methicillin resistant Staphylococcus aureus enterocolitis. BMC Infect Dis 2015 ; 15 : 265. [CrossRef] [PubMed] [Google Scholar]
  20. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors : a randomized, open-label, controlled pilot study. Clin Infect Dis 2014 ; 58 : 1515–1522. [CrossRef] [PubMed] [Google Scholar]
  21. Nationale Agence de sécurité du médicament et des produits de santé. La transplantation de microbiote fécal et son encadrement dans les essais cliniques, juin 2015, actualisation de la version de mars 2014. Paris : ANSM, 2015 [Google Scholar]
  22. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014 ; 312 : 1772–1778. [CrossRef] [PubMed] [Google Scholar]
  23. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection : a randomized clinical trial. JAMA 2016 ; 315 : 142–149. [CrossRef] [PubMed] [Google Scholar]
  24. Malani PN, Rao K. Expanded evidence for frozen fecal microbiota transplantation for Clostridium difficile infection : A fresh take. JAMA 2016 ; 315 : 137–138. [CrossRef] [PubMed] [Google Scholar]
  25. Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection : results of the PUNCH CD study. Clin Infect Dis 2015 ; civ938. [Google Scholar]
  26. Baxter M, Colville A. Adverse events in faecal microbiota transplant : a review of the literature. J Hosp Infect 2016 ; 92 : 117–127. [CrossRef] [PubMed] [Google Scholar]
  27. Solari PR, Fairchild PG, Noa LJ, et al. Tempered enthusiasm for fecal transplant. Clin Infect Dis 2014 ; 59 : 319. [CrossRef] [Google Scholar]
  28. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2015 ; 2 : ofv004. [CrossRef] [PubMed] [Google Scholar]
  29. Baxter M, Ahmad T, Colville A, et al. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis 2015 ; 61 : 136–137. [CrossRef] [PubMed] [Google Scholar]
  30. Costello SP, Tucker EC, La Brooy J, et al. Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 2016 ; 62 : 908–914. [CrossRef] [PubMed] [Google Scholar]
  31. Cassir N, Benamar S, Khalil JB, et al. Clostridium butyricum strains and dysbiosis linked to necrotizing enterocolitis in preterm neonates. Clin Infect Dis 2015 ; 61 : 1107–1115. [CrossRef] [PubMed] [Google Scholar]
  32. Quevrain E, Maubert MA, Michon C, et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut 2016 ; 65 : 415–425. [CrossRef] [PubMed] [Google Scholar]
  33. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008 ; 105 : 16731–16736. [Google Scholar]
  34. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection : a randomized clinical trial. JAMA 2015 ; 313 : 1719–1727. [CrossRef] [PubMed] [Google Scholar]
  35. Lagier JC, Hugon P, Khelaifia S, et al. The rebirth of culture in microbiology through the example of culturomics to study human gut microbiota. Clin Microbiol Rev 2015 ; 28 : 237–264. [CrossRef] [PubMed] [Google Scholar]
  36. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015 ; 350 : 1079–1084. [CrossRef] [PubMed] [Google Scholar]
  37. Lagier JC, Raoult D. Culturomics : une méthode d’étude du microbiote humain. Med Sci (Paris) 2016 ; 32 : 923–925. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  38. Vétizou M, Daillère R, Zitvogel L. Microbiote intestinal et réponses aux thérapies anti-tumorales. Med Sci (Paris) 2016 ; 32 : 974–982. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.